Valuation: Bioventix PLC

Market Cap 78.9M 106M 92.32M 85.93M 149M 10.14B 151M 1.01B 398M 5.05B 399M 390M 16.92B P/E 2026 *
11.3x
P/E 2027 * -
Enterprise Value 74M 99.61M 86.59M 80.6M 140M 9.51B 142M 950M 373M 4.73B 374M 366M 15.87B EV / Sales 2026 *
5.92x
EV / Sales 2027 * -
Free-Float
92.29%
Yield 2026 *
9.93%
Yield 2027 * -
1 week-0.98%
1 month-8.48%
3 months-12.46%
6 months-18.38%
Current year-20.73%
1 week 1,470
Extreme 1470
1,600
1 month 1,470
Extreme 1470
1,700
Current year 1,300
Extreme 1300
1,950
1 year 1,300
Extreme 1300
2,700
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 23/12/2003
Director of Finance/CFO 67 01/07/2020
Director TitleAgeSince
Director/Board Member 67 25/11/2010
Chairman 66 01/11/2004
Director/Board Member 67 01/07/2020
Date Insider Type Main position Quantity % Market Cap.
20/04/26 Free

Chief Financial Officer

9,967 0.1908%
26/11/25 Buy

Chief Financial Officer

150 0.0029%
04/11/25 Buy

Chief Executive Officer

875 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-0.98%-43.02%-60.26% 106M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-1.74%+5.12%+9.58%+46.02% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
Average -1.35%+0.85%+48.05%+85.10% 25.05B
Weighted average by Cap. -1.60%+2.03%+76.81%+128.01%

Financials

2026 *2027 *
Net sales 12.5M 16.83M 14.63M 13.61M 23.61M 1.61B 23.97M 160M 62.98M 800M 63.19M 61.81M 2.68B -
Net income 7.11M 9.57M 8.32M 7.75M 13.43M 914M 13.64M 91.31M 35.84M 455M 35.95M 35.16M 1.53B -
Net Debt -4.89M -6.59M -5.73M -5.33M -9.24M -629M -9.39M -62.83M -24.66M -313M -24.74M -24.2M -1.05B -
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
31/07/26 GBX 1,510.00 -.--% 12,433
30/07/26 GBX 1,510.00 -.--% 15,550
29/07/26 GBX 1,510.00 -.--% 9,932
28/07/26 GBX 1,510.00 +1.34% 21,261
27/07/26 GBX 1,490.00 -2.30% 13,432
Trader
Investor
Global
-
Quality
ESG MSCI
CCC

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BVXP Stock